Breakthroughs and Innovations: Managing Complex Cases in Graft-versus-Host Disease
Host: Paul P. Doghramji, MD, FAAFP
Guest: Corey S. Cutler, MD, MPH, FRCPC
Guest: Doris M. Ponce, MD
Acute graft-versus-host disease (aGVHD) is a common complication of allogeneic hematopoietic stem cell transplantation and is a major cause of morbidity and mortality. Although systemic corticosteroids are traditional first-line treatment for aGVHD, about half of patients are refractory to therapy. So what options are available for the treatment of steroid-refractory aGVHD?